EMA/572669/2010

European Medicines Agency decision

P/177/2010

of 21 September 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for artemether / lumefantrine (Riamet), (EMEA-000777-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/177/2010

of 21 September 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for artemether / lumefantrine (Riamet), (EMEA-000777-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novartis Europharm Limited on 11 December 2009 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 August 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for artemether / lumefantrine (Riamet), tablets and dispersible tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for artemether / lumefantrine (Riamet), tablets and dispersible tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for artemether / lumefantrine (Riamet), tablets and dispersible tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road Horsham, RH12 5AB, West Sussex, United Kingdom

Done at London, 21 September 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/449611/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-000777-PIP01-09

Scope of the application

Active substance(s):

Artemether / lumefantrine

Invented name:

Riamet

Condition(s):

Treatment of Plasmodium falciparum malaria

Pharmaceutical form(s):

Tablets

Dispersible tablets

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted for agreement to the European Medicines Agency on 11 December 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 21 January 2010.

Supplementary information was provided by the applicant on 1 June 2010 and 26 July 2010.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with

     Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population

and

     Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member(s) agree(s) with the above-mentioned recommendation of the Paediatric Committee.

The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 6 August 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The measures and timelines of the agreed Paediatric Investigation Plan and the subset(s) of the paediatric population and condition(s) covered by the waiver

1. Condition(s)

Treatment of Plasmodium falciparum malaria

Authorised indication

Treatment of acute uncomplicated infections due to Plasmodium falciparum malaria in adult, children and infants from 5kg and above.

2. Waiver

2.1. Condition(s)

Treatment of Plasmodium falciparum malaria

2.1.1. Indication(s)

The waiver applies to:

- Paediatric population below 5 kg bodyweight,
- for artemether / lumefantrine tablet, oral use,
- on the grounds that the specific medicinal product in this pharmaceutical form is likely to be unsafe.

- Paediatric population from 5 kg bodyweight and above,
- for artemether / lumefantrine tablet, oral use,
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit as the needs are already covered.

The waiver applies to:

- Children and adolescents weighing 35 kg or more,
- for artemether / lumefantrine dispersible tablet, oral use,
- on the grounds that clinical studies with this specific pharmaceutical form cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

3. Paediatric Investigation Plan

3.1. Condition to be investigated

Treatment of Plasmodium falciparum malaria.

3.1.1. Indication(s) targeted by the PIP

Treatment of acute uncomplicated Plasmodium falciparum malaria.

3.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 35 kg.

3.1.3. Pharmaceutical form(s)

Dispersible tablet (20 mg artemether / 120 mg lumefantrine).

3.1.4. Studies

Area	Number of studies	Description
Quality	1	Study 1: development of dispersible tablet for oral use
Non-clinical	2	Study 2: Juvenile development dose-ranging finding study of oral artemether in rats Study 3: juvenile development study in rats of artemether
Clinical	2	Study 4: Randomised, investigator-blinded, multicentre, parallel-group trial to compare the efficacy, safety and tolerability of the artemether/lumefantrine dispersible tablet versus the artemether/lumefantrine tablet administered crushed in the treatment of acute uncomplicated Plamodium falciparum malaria in infants and children from 5 kg to less than 35 kg body weight. Study 5: Open-label, single arm, multicentre trial to evaluate the pharmacokinetics, efficacy and safety of artemether/lumefantrine dispersible tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in neonates and infants who weigh less than 5 kg

4. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2013
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

EU Number	Invented Name	Strength	Pharma-ceutical form	Route of admini-stration	Packa-ging	Content (concen-tration)	Package size	Indication
N/A	Riamet	20 mg/120 mg artemether /lumefantrine	Tablet	Oral use	N/A	N/A	N/A	treatment of acute uncomplicated Plasmodium Falciparum malaria in adult, children and infants of 5 kg and above